In addition, it has been hypothesized that the possible role of glucagon-like receptor agonists (GLP1-Ras) in the modulation and interaction of these two hepatokines could provide an explanation of the therapeutic potential for the treatment of MASLD with these drugs. The gene discussed is GLP1R; the disease is metabolic dysfunction-associated steatotic liver disease.